Pipeline news

• Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  24 March 2021

  

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (the “Company” or “Marinus”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the grant of inducement awards to 12 new employees. 

• binx health™ Collaborates with Amazon Business for Delivery of COVID-19 Sample Collection Kits to U.S. Businesses, Schools and Governments

  17 March 2021

  

  binx health, a population health technology company that provides convenient healthcare solutions, announced today that its FDA emergency-use authorized at-home nasal swab COVID-19 Sample Collection Kit is now available for delivery to Amazon Business customers across the United States. binx health is a proven leader in accurate, convenient testing and is aiming to redefine population health by making health testing more accessible.

• There’s A New Coil In Town, So What’s The Deal?

  15 March 2021 Sarah Graham / Refinery29

  

  The Ballerine IUB (intrauterine ball) was developed by OCON Medical and launched in Austria in 2014. Much of Europe has had the IUB as an option for years and it’s also available in parts of Africa and the Middle East. Meanwhile, in the UK, it’s been available privately since March 2017. It was originally due to be rolled out on the NHS in 2020 but – like so many things – coronavirus stopped it in its tracks.

• Clearside Biomedical Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

  10 March 2021

  

  Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, today reported financial results for the fourth quarter and year ended December 31, 2020 and provided a corporate update.

• Veteran Healthcare Leader David P. King Joins binx health Board of Directors

  09 March 2021

  

  binx health today announced the addition of David P. King to its Board of Directors. Mr. King served for nearly 13 years as Chairman and CEO of LabCorp, where he spearheaded the company’s transformation from a pure-play clinical laboratory into a global leader in life sciences, tripling the size of the company to more than $11.5 billion in revenue and nearly 65,000 employees.

• Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter 2020 Financial Results

  09 March 2021

  

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today provided an update on its clinical and regulatory development activities and reported its financial results for the fourth quarter and fiscal year ended December 31, 2020.

• Syndax Pharmaceuticals Reports Fourth Quarter 2020 Financial Results and Provides Clinical and Business Update

  08 March 2021

  

  Syndax Pharmaceuticals, Inc.  ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the fourth quarter ended  December 31, 2020 . In addition, the Company provided a clinical and business update.

• Atea Pharmaceuticals Presents Favorable Phase 1 Results for AT-527 at 28th Annual Conference on Retroviruses and Opportunistic Infections

  06 March 2021

  

  Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today presented results from the Phase 1 study of AT-527 in healthy volunteers at the 28th Annual Conference on Retroviruses and Opportunistic Infections (CROI) in a Science Spotlight presentation. AT-527 is an orally administered, direct-acting antiviral developmental agent derived from Atea’s purine nucleotide prodrug platform and is in Phase 2 clinical development for the treatment of COVID-19.

• Clearside Biomedical Announces Completion of Patient Dosing in First Cohort of Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

  03 March 2021

  

  Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today completion of dosing in the first cohort of OASIS, its ongoing Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with neovascular age-related macular degeneration (wet AMD).

• Marinus Pharmaceuticals Unveils New Brand as the Company Prepares for Commercialization

  23 February 2021

  

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the enrollment of the first patient in a Phase 3 clinical trial of IV ganaxolone (RAISE trial) for the treatment of refractory status epilepticus (RSE), a life-threatening occurrence of continued or intermittent seizures lasting more than five minutes in duration without recovery of consciousness. RSE is considered a medical emergency that can cause permanent brain damage or death if not quickly controlled.